Epidemic Intelligence Service, Division of Scientific Education and Professional Development, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Arkansas Department of Health, Little Rock, Arkansas, USA.
Clin Infect Dis. 2020 Oct 23;71(7):e178-e185. doi: 10.1093/cid/ciz1120.
In July 2018, the Arkansas Department of Health (ADH) was notified by hospital A of 3 patients with bloodstream infections (BSIs) with a rapidly growing nontuberculous Mycobacterium (NTM) species; on 5 September 2018, 6 additional BSIs were reported. All were among oncology patients at clinic A. We investigated to identify sources and to prevent further infections.
ADH performed an onsite investigation at clinic A on 7 September 2018 and reviewed patient charts, obtained environmental samples, and cultured isolates. The isolates were sequenced (whole genome, 16S, rpoB) by the Centers for Disease Control and Prevention to determine species identity and relatedness.
By 31 December 2018, 52 of 151 (34%) oncology patients with chemotherapy ports accessed at clinic A during 22 March-12 September 2018 had NTM BSIs. Infected patients received significantly more saline flushes than uninfected patients (P < .001) during the risk period. NTM grew from 6 unused saline flushes compounded by clinic A. The identified species was novel and designated Mycobacterium FVL 201832. Isolates from patients and saline flushes were highly related by whole-genome sequencing, indicating a common source. Clinic A changed to prefilled saline flushes on 12 September as recommended.
Mycobacterium FVL 201832 caused BSIs in oncology clinic patients. Laboratory data allowed investigators to rapidly link infections to contaminated saline flushes; cooperation between multiple institutions resulted in timely outbreak resolution. New state policies being considered because of this outbreak include adding extrapulmonary NTM to ADH's reportable disease list and providing more oversight to outpatient oncology clinics.
2018 年 7 月,阿肯色州卫生部(ADH)接到医院 A 的通知,称有 3 名血源感染(BSI)患者感染了一种快速生长的非结核分枝杆菌(NTM);2018 年 9 月 5 日,又报告了 6 例 BSI。这些患者均为 A 诊所的肿瘤患者。我们进行了调查,以确定感染源并防止进一步感染。
ADH 于 2018 年 9 月 7 日在 A 诊所进行了现场调查,查阅了患者病历,采集了环境样本并进行了培养分离。分离株由疾病预防控制中心进行测序(全基因组、16S、rpoB),以确定物种身份和相关性。
截至 2018 年 12 月 31 日,在 2018 年 3 月 22 日至 9 月 12 日期间在 A 诊所接受化疗置管的 151 名肿瘤患者中,有 52 名(34%)患有 NTM BSI。感染患者在风险期内接受的生理盐水冲洗明显多于未感染患者(P<0.001)。A 诊所的 6 个未使用的生理盐水冲洗液中均生长出 NTM。鉴定出的物种是一种新型的分枝杆菌,命名为 FVL 201832。患者和生理盐水冲洗液的分离株通过全基因组测序高度相关,表明存在共同来源。A 诊所按照建议于 2018 年 9 月 12 日改为使用预充式生理盐水冲洗液。
FVL 201832 分枝杆菌引起了肿瘤患者的 BSI。实验室数据使调查人员能够迅速将感染与受污染的生理盐水冲洗液联系起来;多个机构的合作使疫情得到及时解决。由于此次疫情,阿肯色州正在考虑新的州政策,包括将肺部外 NTM 添加到 ADH 的报告疾病列表中,并对外科肿瘤诊所提供更多监督。